Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.

Histopathology - 1 Jun 2015

Watanabe Yukio, Shiraishi Kouya, Takahashi Fumiaki, Yoshida Akihiko, Suzuki Kenji, Asamura Hisao, Takeuchi Masahiro, Furuta Koh, Tsuta Koji

Abstract excerpt

AIMS: Pulmonary adenosquamous carcinoma (ASC) is more aggressive than adenocarcinoma (AC) and squamous cell carcinoma (SCC). The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC. METHODS AND RESULTS: Surgically resected ASC samples from 65 patients were analysed. We examined the expression of β III-tubulin, thymidylate synthase, breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Adenosquamous

Share to Carcinoma, Squamous Cell

Share to Gene Expression Regulation, Neoplastic

Share to Lung Neoplasms

Source

Identifiers

PMID: 25257380
DOI: 10.1111/his.12556

Genes

EGFR
ALK
KRAS
MET
ROS1
RRM1
BRAF
RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.PMID 25257380Read ↗

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lungSemantic proximity Read ↗

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.Semantic proximity Read ↗

[Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma].Semantic proximity Read ↗

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.Semantic proximity Read ↗

Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data.Semantic proximity Read ↗

Molecular heterogeneity in histomorphologic subtypes of lung adeno carcinoma represents a challenge for treatment decision.Semantic proximity Read ↗

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.Semantic proximity Read ↗

Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.Semantic proximity Read ↗

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profilingSemantic proximity Read ↗

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.